The last decade has seen a substantial growth in the use of high-throughput molecular technologies in cancer research across the SKCCC. Efficient utilization of the data generated by these experiments is of strategic scientific importance and requires bioinformatics support. The bioinformatics shared resource guarantees the availability of comprehensive bioinformatics expertise to Cancer Center members. This resource comprises faculty and support staff able to support data acquisition (including study design, feasibility of objectives, availability of public-access genomic information, data storage, and data annotation), statistical quality control (including artifact detection, preprocessing, and normalization of data from genomic technologies), data analysis (including visualization, modeling, inference and interpretation), and development of innovative customized bioinformatics tools, and education. This resource stabilizes and expands existing high-quality expertise in the areas of computational molecular biology, bioinformatics, and computing-intensive statistical genetics. Organizing this expertise as a Shared Resource is a costeffective approach to ensure that qualified bioinformatics support is readily available to investigators from all programs in the center. Resource members are in an ideal position to initiate and promote interdisciplinary interactions among cancer research projects led by different investigators, and thus speed the bi-directional exchange between basic and clinical science. Members of the Shared resource will also continue to develop their own agenda of cancer bioinformatics research, to participate in educational activities in the Cancer Center and across the University, and to be active in the profession. These dimensions will be funded separately from this submission, but are critical in the development of a group able to provide Cancer Center investigators with reliable, state-of-the-art, and broad-based expertise.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA006973-48
Application #
8117680
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2010-05-01
Budget End
2011-04-30
Support Year
48
Fiscal Year
2010
Total Cost
$250,908
Indirect Cost
Name
Johns Hopkins University
Department
Type
DUNS #
001910777
City
Baltimore
State
MD
Country
United States
Zip Code
21218
Jackson, Sadhana; Weingart, Jon; Nduom, Edjah K et al. (2018) The effect of an adenosine A2A agonist on intra-tumoral concentrations of temozolomide in patients with recurrent glioblastoma. Fluids Barriers CNS 15:2
Dejea, Christine M; Fathi, Payam; Craig, John M et al. (2018) Patients with familial adenomatous polyposis harbor colonic biofilms containing tumorigenic bacteria. Science 359:592-597
Gorin, Michael A; Rowe, Steven P; Patel, Hiten D et al. (2018) Prostate Specific Membrane Antigen Targeted 18F-DCFPyL Positron Emission Tomography/Computerized Tomography for the Preoperative Staging of High Risk Prostate Cancer: Results of a Prospective, Phase II, Single Center Study. J Urol 199:126-132
Bharti, Santosh K; Mironchik, Yelena; Wildes, Flonne et al. (2018) Metabolic consequences of HIF silencing in a triple negative human breast cancer xenograft. Oncotarget 9:15326-15339
Nagai, Kozo; Hou, Lihong; Li, Li et al. (2018) Combination of ATO with FLT3 TKIs eliminates FLT3/ITD+ leukemia cells through reduced expression of FLT3. Oncotarget 9:32885-32899
Sturgeon, Kathleen M; Hackley, Renata; Fornash, Anna et al. (2018) Strategic recruitment of an ethnically diverse cohort of overweight survivors of breast cancer with lymphedema. Cancer 124:95-104
Baena-Del Valle, Javier A; Zheng, Qizhi; Esopi, David M et al. (2018) MYC drives overexpression of telomerase RNA (hTR/TERC) in prostate cancer. J Pathol 244:11-24
Jiang, Wei; Zhou, Xiaoyan; Li, Zengxia et al. (2018) Prolyl 4-hydroxylase 2 promotes B-cell lymphoma progression via hydroxylation of Carabin. Blood 131:1325-1336
Zarif, Jelani C; Antonarakis, Emmanuel S (2018) Targeting ELK1: a wELKome addition to the prostate cancer armamentarium. AME Med J 3:
Martino, Thiago; Kudrolli, Tarana A; Kumar, Binod et al. (2018) The orally active pterocarpanquinone LQB-118 exhibits cytotoxicity in prostate cancer cell and tumor models through cellular redox stress. Prostate 78:140-151

Showing the most recent 10 out of 2393 publications